Waters this week named the Center for Proteomics at the Translational Genomics Research Institute as one of its Centers of Innovation.
In particular, the company cited Konstantinos Petritis, head of TGen's Center for Proteomics, and his research team for contributions to proteomics and protein biomarker discovery and verification.
The Phoenix, Ariz.-based institute is one of 13 Centers of Innovation worldwide. It currently uses a Waters Synapt G2 mass spec and several Acquity UPLC/Xevo TQ-S instrument systems to support its proteomics research.
"One of our core strengths is in biomarker discovery and verification," Petritis said in a statement. "With the infrastructure we've put into place, we are making steady progress in the development of diagnostic and prognostic biomarkers for lung, colon, breast, and pancreatic cancer as well as other diseases."
"By formalizing our relationship with them we want to help TGen achieve its objectives and make personalized medicine a reality, partly by taking technology to the next level," said Mark Groudas, Waters senior vice president, Americas business operations.